Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy

As patients with non-small cell lung cancer (NSCLC) and wild-type epidermal growth factor receptor (EGFR) are resistant to treatment with erlotinib or gefitinib, potential chemosensitizers are required to potentiate wild-type EGFR NSCLC cells to erlotinib/gefitinib treatment. The present study repor...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Mol Med Rep
Main Authors: Li, Yang-Ling, Hu, Xiu, Li, Qing-Yu, Wang, Fei, Zhang, Bo, Ding, Ke, Tan, Bi-Qin, Lin, Neng-Ming, Zhang, Chong
Formato: Artigo
Idioma:Inglês
Publicado: D.A. Spandidos 2018
Assuntos:
Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6131653/
https://ncbi.nlm.nih.gov/pubmed/30106133
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mmr.2018.9347
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares